Clinical Trials - Phase III
Filter News
Found 22,560 articles
-
AbbVie's Experimental Hepatitis C Regimen Associated With High Cure Rates In Late-Stage Studies
4/15/2014
-
Intercept Pharmaceuticals Reports Additional Positive Data From POISE Trial At EASL Late-Breaker Session
4/14/2014
-
BioAlliance Pharma Announces A New Positive DSMB Recommendation To Continue Its Phase III Clinical Trial With Livatag® In Primary Liver Cancer
4/14/2014
-
BioAlliance Pharma Announces A New Positive DSMB Recommendation To Continue Its Phase 3 Clinical Trial With Livatag® In Primary Liver Cancer
4/14/2014
-
Portola Pharmaceuticals, Inc. Announces Publication Of Phase 3 APEX Study Design And Rationale In American Heart Journal
4/14/2014
-
Mast Therapeutics Announces New Data Supporting MST-188 In Sickle Cell Disease
4/14/2014
-
Ipsen Announces A First Set Of Results On Positive Phase III Clinical Study Of Dysport® In The Treatment Of Adults Suffering From Upper Limb Spasticity At The 8th World Congress For Neurorehabilitation In Istanbul
4/14/2014
-
Enanta Pharmaceuticals, Inc. Announces Detailed Data From TURQUOISE-II Study In Chronic Hepatitis C Patients With Cirrhosis Being Presented At The European Association For The Study Of The Liver (EASL) Meeting
4/14/2014
-
Bristol-Myers Squibb Company's Hepatitis C Drug Cures Up To 90 Percent In Phase 3 Study
4/11/2014
-
Actinium Pharmaceuticals, Inc. Analyst Report: High Potential Emerging Biopharmaceutical Firm Nearing Phase 3 Trial Commencement For Innovative Cancer Treatments
4/11/2014
-
Biogen Idec, Inc. (Massachusetts)'s Blood Disorder Drug Succeeds In Phase 3 Trial
4/10/2014
-
Cyclacel Pharmaceuticals, Inc. Release: Independent Investigators Present Non-Clinical Data Providing Rationale For Sapacitabine Combination Treatment With Bcr-Abl Inhibitors In CML
4/10/2014
-
Gilead Sciences, Inc. Announces Results From Study Of Sovaldi® For Retreatment Of Chronic Hepatitis C In Patients Not Cured With Prior Antiviral Therapy
4/10/2014
-
Alkermes plc Pulls Off Phase 3 Win for Long-Lasting Schizophrenia Drug
4/9/2014
-
Forest Laboratories, Inc. And Almirall Provide Update On The Fixed Dose Combination Of Aclidinium And Formoterol In The U.S.
4/9/2014
-
Data Presented At American Association for Cancer Research Support Potential Of Peregrine Pharmaceuticals, Inc.'s PS-Targeting Immunotherapy Bavituximab To Enhance Anti-Tumor And Immune-Stimulating Effects Of Anti-CTLA-4 And Anti-PD-1 Treatments In Models
4/9/2014
-
Aegerion Pharmaceuticals, Inc. Initiates Phase 3 Clinical Trial In Japan To Evaluate Lomitapide For Treatment Of Homozygous Familial Hypercholesterolemia (Hofh)
4/9/2014
-
Pfizer Inc. Continues Its Streak, Phase 2 Breast Cancer Results Wows Investors And Researchers
4/8/2014
-
Northwest Biotherapeutics Again Sets Feuerstein Record Straight; Corrects His False Claims
4/8/2014
-
Data Presented At American Association for Cancer Research Support Potential Of Combining Peregrine Pharmaceuticals, Inc.'s PS-Targeting Immunotherapy Agent Bavituximab With Irradiation In Lung Cancer
4/8/2014